<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04757987</url>
  </required_header>
  <id_info>
    <org_study_id>764/2019</org_study_id>
    <secondary_id>K43TW011442</secondary_id>
    <nct_id>NCT04757987</nct_id>
  </id_info>
  <brief_title>An Observational Study of Distress, Immune Function, and Pain in HIV.</brief_title>
  <official_title>An Observational Study of Shared Variation and Reciprocal Influences: Distress, Immune Function and Pain in HIV.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Cape Town</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fogarty International Center of the National Institute of Health</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Brigham and Women's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Adelaide</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Michigan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Cape Town</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This case-control study focuses on pain in HIV, which is common despite antiretroviral&#xD;
      therapy and compromises quality of life, mental health and daily functioning. Specifically,&#xD;
      it will investigate the relationships between psychosocial distress, inflammation and pain in&#xD;
      HIV.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      We plan to recruit 100 people and follow them for 6 months, taking repeated measures.&#xD;
      Participants who report persistent pain at enrolment will be assessed at 0 (baseline), 2, 4,&#xD;
      and 6 months. Participants who report no pain at enrolment will be assessed at 0 (baseline)&#xD;
      and 6 months. All participants will also be invited to participate in weekly remote&#xD;
      assessment of selected self-reported outcomes.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 11, 2021</start_date>
  <completion_date type="Anticipated">December 23, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 23, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Hopkins Symptom Checklist 25-item questionnaire</measure>
    <time_frame>Baseline</time_frame>
    <description>Psychosocial distress</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Provoked inflammatory response</measure>
    <time_frame>Baseline</time_frame>
    <description>Multiplex assay</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Brief Pain Inventory</measure>
    <time_frame>Baseline</time_frame>
    <description>Pain intensity</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Secondary hyperalgesia (surface area)</measure>
    <time_frame>Baseline assessment only</time_frame>
    <description>Induced in a subgroup</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Brief Pain Inventory</measure>
    <time_frame>Baseline</time_frame>
    <description>Pain locations</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Chronic Pain</condition>
  <condition>HIV</condition>
  <condition>Distress, Emotional</condition>
  <condition>Immune System and Related Disorders</condition>
  <condition>Central Sensitisation</condition>
  <arm_group>
    <arm_group_label>Pain-free</arm_group_label>
    <description>Report persistent pain at enrolment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Persistent pain</arm_group_label>
    <description>Report no pain at enrolment</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Pain</intervention_name>
    <description>As above</description>
    <arm_group_label>Persistent pain</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Primary care clinic in South Africa.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  HIV-positive with viral suppression&#xD;
&#xD;
          -  report either persistent pain or no pain at enrolment&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  pregnancy&#xD;
&#xD;
          -  acute psychiatric condition requiring urgent care&#xD;
&#xD;
          -  cognitive impairment preventing full participation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Victoria J Madden, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Cape Town</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Victoria J Madden, PhD</last_name>
    <phone>+27 21 650 3683</phone>
    <email>tory.madden@uct.ac.za</email>
  </overall_contact>
  <location>
    <facility>
      <name>Community Health Clinic [name withheld due to risk to participants]</name>
      <address>
        <city>[City Withheld Due To Risk To Participants]</city>
        <state>Western Cape</state>
        <zip>7784</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Natacha Berkowitz</last_name>
      <phone>+27 21 400 6864</phone>
      <email>Natacha.Berkowitz@capetown.gov.za</email>
    </contact>
  </location>
  <location_countries>
    <country>South Africa</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>February 9, 2021</study_first_submitted>
  <study_first_submitted_qc>February 14, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 17, 2021</study_first_posted>
  <last_update_submitted>October 1, 2021</last_update_submitted>
  <last_update_submitted_qc>October 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Cape Town</investigator_affiliation>
    <investigator_full_name>Victoria Madden</investigator_full_name>
    <investigator_title>Senior lecturer</investigator_title>
  </responsible_party>
  <keyword>Chronic pain</keyword>
  <keyword>HIV</keyword>
  <keyword>Innate Immune Response</keyword>
  <keyword>Mental health</keyword>
  <keyword>Hyperalgesia, secondary</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chronic Pain</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>The final dataset will include demographic, health history, psychological, and physiological data. An important priority when considering sharing of these data is participant confidentiality, particularly considering the stigma and personal social risk associated with HIV+ status in South Africa. If the data can be adequately stripped of identifiers so as to eliminate risk to participants, then the final, de-identified data set will be made available to qualified users through a data sharing platform, and subject to a sharing agreement that includes (1) a commitment to using the data only for research purposes and not to identify any individual participant; and (2) a commitment to securing the data using appropriate computer technology.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

